Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (0.00%) As of 06/11/2025 10:13 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock SCPS vs. CALA, EVLO, CMRA, GNCAQ, GNCA, ARDS, HSTO, STAB, CLVR, and EFTRShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Calithera Biosciences (CALA), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Histogen (HSTO), Statera Biopharma (STAB), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Its Competitors Calithera Biosciences Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Histogen Statera Biopharma Clever Leaves eFFECTOR Therapeutics Scopus BioPharma (NASDAQ:SCPS) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation. Which has higher earnings and valuation, SCPS or CALA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/ACalithera BiosciencesN/AN/A-$39.65MN/AN/A Is SCPS or CALA more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Calithera Biosciences N/A N/A N/A Which has more risk and volatility, SCPS or CALA? Scopus BioPharma has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -2.56, meaning that its share price is 356% less volatile than the S&P 500. Does the media refer more to SCPS or CALA? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Calithera Biosciences Neutral Does the MarketBeat Community prefer SCPS or CALA? Calithera Biosciences received 339 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 55.09% of users gave Calithera Biosciences an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesCalithera BiosciencesOutperform Votes34155.09% Underperform Votes27844.91% SummaryScopus BioPharma beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13K$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7827.1420.06Price / SalesN/A255.49419.32157.08Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net Income-$11.61M$143.93M$3.23B$247.88M7 Day PerformanceN/A3.84%2.83%2.63%1 Month PerformanceN/A11.20%9.02%6.36%1 Year PerformanceN/A4.18%31.36%14.05% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009CALACalithera Biosciences0.6238 of 5 stars$0.00flatN/A-90.0%$10KN/A0.0060Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00-66.7%N/A-99.8%$5K$3.09M0.0030Gap DownHSTOHistogenN/A$0.00flatN/A-99.4%$5K$19K0.0020STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020CLVRClever LeavesN/A$0.00flatN/A-100.0%$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00+100.0%N/A-100.0%$1K$3.55M0.0010Gap Up Related Companies and Tools Related Companies Calithera Biosciences Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Histogen Competitors Statera Biopharma Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCPS Stock Free SCPS Stock Alerts